Standard models in evidence synthesis work well in settings characterized by a large evidence base, the absence of effect modifiers, and connected networks. Handling sparse data, substantial between-study heterogeneity and disconnected studies, however, poses challenges to researchers and requires advanced methodology.
In the absence of head-to-head studies, evidence synthesis is a well-established technique to indirectly compare novel and established interventions in various disease areas. In standard settings, the most established methods for various outcome types work well and result in realistic effect estimates. However, there are a variety of situations when standard methods may no longer be sufficient:
- if there is only a sparse network of evidence
- if there is a large amount of between-study heterogeneity
- if the network is disconnected
Key Topics Include:
- General introduction into the objectives of conducting evidence synthesis
- Description of typical situations of “non-standard” data, including sparse networks of evidence, a large amount of between-study heterogeneity, or disconnected networks
- Advanced methods to address non-standard data, including the use of informative priors, subgroup analyses, meta-regression and multi-level meta regression, and matching-adjusted indirect comparisons (MAICs)
- Case studies illustrating how these advanced methods of evidence synthesis are applied on actual data
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.
Presenters
Senior Health Economist
Global Health Economics, Outcomes Research and Epidemiology
ICON
Katrin Haeussler joined ICON in 2017. At ICON, Katrin mainly works in the area of evidence synthesis, conducting analyses in both Bayesian and frequentist settings.
Lead Epidemiologist
Global Health Economics, Outcomes Research and Epidemiology
ICON
Matthias Hunger joined ICON in 2014. In his current role he is involved in all statistical components of research projects, from study design, protocol development, and data analysis to writing study reports or research manuscripts.
Senior Research Fellow
Department of Statistical Science
University College London
Nathan Green has a number of years experience working on a wide range of projects across government and academia in defense and health, and currently works in the Department of Statistical Science at UCL.
Production Partner
ICON
ICON is a global provider of consulting, and outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We focus our innovation on the factors that are critical to our clients - reducing time to market, reducing cost and increasing quality.
Additional Content From ICON
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Social Media Data: Opportunities and Insights for Clinical Research
Hear four experts from ICON and Kap Code provide insights on how to collect, use, analyze, and interpret social media data in different contexts. These experts share knowledge from over fifteen years of successfully developing and adapting algorithms to treat this kind of data.
Additional Content From HealthEconomics.Com
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Watch a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who provide a practical overview of how and why to use data from Medicare for real world studies.
Related Content
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.
Economic Impact of Representativeness in Clinical Trials: How Real-World Data Can Help
This panel of real-world evidence (RWE) experts explore the economic impact and role of RWE in improving representativeness of research.
Stay Ahead of the Game: Learn How to Conduct an Evidence-Based GVD Faster and Smarter to Improve Market Access
Hear several experts address systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.